LGC Biosearch Technologies launches Amp-Seq One: A revolutionary one-step targeted genotyping by sequencing workflow delivering speed and precision to enhance genomics in commercial breeding.

31 October 2024

LGC Biosearch Technologies launches Amp-Seq One: A revolutionary one-step targeted genotyping by sequencing workflow delivering speed and precision to enhance genomics in commercial breeding. Set to become the fastest amplicon sequencing protocol on the market, Amp-Seq One offers reduced hands-on time and doubled throughput for customers.

Read More
Holland & Barrett marks one of the largest Informed Sport certifications to date

16 October 2024

Holland & Barrett has inserted their mark on Informed Sport history, as they now hold the record as the company to certify the most products at the beginning of a partnership. With more than 60 product variances through their new and improved range of Precision Engineered Sports nutrition, Holland & Barrett has also become one of the largest ranges in the UK to be certified by Informed Sports.

Read More
LGC Clinical Diagnostics and AccuGenomics partner to enhance cancer testing accuracy and drive better patient outcomes

08 October 2024

LGC, a global leader in clinical diagnostics and genomics, announces a new strategic partnership with AccuGenomics, a pioneer in molecular diagnostic development. This collaboration is set to drive innovation in clinical diagnostic tools by combining LGC’s expertise in quality control solutions with AccuGenomics’ advanced next- generation sequencing (NGS) monitoring technologies.

Read More
LGC Clinical Diagnostics launches a comprehensive DYPD reference material to advance personalized cancer treatment and pharmacogenomics

27 September 2024

LGC Clinical Diagnostics, a leader in quality solutions for molecular diagnostics, is delighted to announce the launch of the Seraseq® DPYD DNA Mutation Mix. This launch marks LGC Clinical Diagnostics’ entry into the rapidly expanding field of pharmacogenomics, furthering its commitment to personalized medicine. This cutting-edge reference material is designed for developing, validating, and routinely evaluating Next Generation Sequencing (NGS) assays and other molecular assays that detect critical mutations in the DPYD gene.

Read More